Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 101 to 150 of 392

Guidance and quality standards awaiting development
TitleType
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]Technology appraisal guidance
Efzimfotase alfa for treating hypophosphatasia [ID6633]Technology appraisal guidance
Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]Technology appraisal guidance
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]Technology appraisal guidance
Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [TSID12377]Technology appraisal guidance
Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [TSID12390]Technology appraisal guidance
Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [ID6532]Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]Technology appraisal guidance
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]Technology appraisal guidance
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [ID6759]Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]Technology appraisal guidance
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]Technology appraisal guidance
Excimer Laser Trabeculotomy (ELT) for glaucomaHealthTech guidance
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]Technology appraisal guidance
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]Technology appraisal guidance
Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]Technology appraisal guidance
Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]Technology appraisal guidance
GamblingQuality standard
Gantenerumab for treating early Alzheimer's disease [TSID10668]Technology appraisal guidance
Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]Technology appraisal guidance
Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]Technology appraisal guidance
Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babiesHealthTech guidance
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]Technology appraisal guidance
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]Technology appraisal guidance
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]Technology appraisal guidance
GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]Technology appraisal guidance
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]Technology appraisal guidance
GoutQuality standard
Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [TSID12379]Technology appraisal guidance
Heart valve disease in adultsQuality standard
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]Technology appraisal guidance
Ianalumab for treating active Sjogren's syndrome [ID6634]Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]Technology appraisal guidance
ID6611 Obesity, overweight - semaglutide (including review of TA875)Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All